Pharming Group N.V.
PHAR$909M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaLEIDEN404 employees
Drugs in Pipeline
5
Phase 3 Programs
4
Upcoming Catalysts
5
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
PHAR News
Catalyst Timeline
5 upcoming, 0 past
Drug Pipeline
Leniolisib
PIDs Linked to PI3K
i.v. recombinant human C1 inhibitor
Genetic Disorders
recombinant human C1 inhibitor
Hereditary Angioedema
rhC1INH
Hereditary Angioedema
Ruconest
Confirmed Coronavirus Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Leniolisib | Phase 3 | PIDs Linked to PI3K | - | - |
i.v. recombinant human C1 inhibitor | Phase 3 | Genetic Disorders | - | - |
recombinant human C1 inhibitor | Phase 3 | Hereditary Angioedema | - | - |
rhC1INH | Phase 3 | Hereditary Angioedema | - | - |
Ruconest | Phase 2 | Confirmed Coronavirus Disease | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply